Biotechnology is advancing on multiple simultaneous technology frontiers — mRNA platform technology extending from vaccines to therapeutics, RNA interference achieving durable gene silencing across multiple disease areas, CRISPR gene editing approaching clinical validation in rare genetic disease, antibody discovery platforms generating next-generation bispecific and trispecific antibodies, and AI-driven drug discovery compressing development timelines. The companies that most effectively translate these platform technologies into commercially successful products will define the competitive hierarchy of biotechnology for the next decade.

Regeneron's VelocImmune antibody discovery platform has generated more FDA-approved antibody therapies than any other platform in history. Alnylam's RNAi technology has produced five approved products across metabolic and neurological disease. Vertex's CASGEVY — the first approved CRISPR gene editing therapy — represents the commercial validation of gene editing as a therapeutic modality. Amgen's half-life extension technology and bispecific antibody platform are the foundation of its next-generation oncology pipeline.

Emerging Technologies Assessed: mRNA Therapeutics / RNA Interference / CRISPR Gene Editing / Bispecific and Multispecific Antibodies / ADC Antibody-Drug Conjugates / Cell Therapy CAR-T / Gene Therapy AAV / AI Drug Discovery / Plasma Fractionation Innovation